Cephalon submits Treanda NDA for relapsed indolent non-Hodgkin's lymphoma |
|
|
|
Published
:
Mon, 31 Dec 2007 16:40
|
BOSTON (Thomson Financial) - Cephalon Inc. said Monday it submitted a new drug application to the Food and Drug Administration for Treanda, the company's treatment for relapsed indolent non-Hodgkin's lymphoma.The Frazer, Pa.-based drug manufacturer said the submission is supported by three studies in patients with non-Hodgkin's lymphoma, including one in combination with rituximab, that showed patients treated with Treanda had a high rate of response and a manageable and tolerable side effect profile.Cephalon said the National Cancer Institute estimates 30,000 people in the U.S. will be diagnosed with indolent non-Hodgkin's lymphoma in 2007.The stock fell 59 cents to $71.81, down 0.8% intraday.Greg Saulniergs/pcCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1449.80 |
+51.73 (
3.63 %)
|
| SYMBOL (
2008-12-02 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
1347.00 |
+51.00 (
4.02 %)
|
| SYMBOL (
2008-12-02 )
|
| LAST |
CHANGE
|
|
IBM
(
4:01pm ) |
|
79.84 |
+2.94 (
3.78 %)
|
| SYMBOL (
2008-12-02 )
|
| LAST |
CHANGE
|
|
GOOGLE
(
4:00pm ) |
|
275.11 |
+9.12 (
3.37 %)
|
|
|
Print this Story
Cephalon sees positive results from Treanda in two Phase III trials 